Overview

As of 2 February 2025, Parexel, a leading global contract research organization (CRO), has announced ambitious plans to expand its operations in India. This strategic move underscores a broader industry trend: diversifying clinical trial geographies in response to geopolitical instability and cost pressures.

India: Rising as a Preferred Early-Stage Trial Destination

Sanjay Vyas, head of Parexel’s India operations, highlighted that disruptions such as the Russia–Ukraine conflict and the shifting dynamics in global drug development are prompting sponsors to reconsider traditional trial locations. India now presents a compelling alternative, offering robust infrastructure, skilled manpower, and favorable cost structures.

To support this expansion, Parexel plans to grow its local workforce by over 2,000 employees in the next three to five years, further strengthening a presence that currently spans 100 to 150 trial sites across key states including Maharashtra, Karnataka, Telangana, and Tamil Nadu.

Advantages Driving the Shift

• Economic Efficiency: The markedly lower costs of conducting trials in India make it especially attractive for early-phase studies, where speed and budget constraints are critical.
• Regulatory Resilience: With global supply chain disruptions and geopolitical conflicts, India is viewed as a relatively stable alternative for trial continuity.
• Market Growth: India’s clinical trial data market is projected to reach $1.51 billion by 2025, signalling substantial growth and investor confidence.

Challenges and Road Ahead

Despite the promising trajectory, Vyas acknowledged there are hurdles to overcome:

• Regulatory Standardization: A lack of harmonized regulations, particularly for early-stage trials, remains a concern.
• Awareness and Infrastructure Gaps: Patient and physician understanding of experimental treatments is limited, and setting up trial sites in remote areas poses significant logistical challenges.

Strategic Implications

Parexel’s planned expansion signals India’s increasing role in the global clinical research ecosystem. For investors and biopharma sponsors, this move opens avenues to:

• Accelerate trial timelines with cost-effective solutions in early-stage development.
• Tap into diverse patient populations for broader data representation.
• Build resilience into clinical trial strategies amid rising geopolitical uncertainties.

This aligns with broader trends in the industry—such as the push toward more geographically diversified, patient-centric, and agile clinical trial models in 2025.